Clinical Trial

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-25.
Trial Details
NCT Number NCT06751485
Lead Sponsor Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Conditions Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers
Enrollment 430 participants
Start Date 2025-01-15
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-31